CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
January 08, 2020
 Clinical Research Associate (CRA) Volunteers Needed for Endpoint & Disease Site Executive Committees! The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Gastrointestinal and Genitourinary Disease Site Committee Executives as well as Supportive Care Committee. Read More |
Commonwealth Neuroendocrine Tumour (CommNETs) 2019 Research WorkshopPublished: January 08, 2020Category: News  The Commonwealth Neuroendocrine Tumour (CommNETs) Research Collaborative held their annual research workshop on December 7 & 8th 2019 in Tokyo Japan. Operating within the auspices of CCTG and AGITG (Australasian Gastro-Intestinal Trials Group) CommNETs provides a valuable forum for NET research collaboration among Canadian, Australian and New Zealand clinicians, researchers and patient representatives. Read More |
 Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials. Read More |
Publication - Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour CarePublished: January 08, 2020Category: Publications  Quality performance indicators (QPIs) are used to monitor the delivery of cancer care. Neuroendocrine tumours (NETs) are a family of individually uncommon cancers that derive from neuroendocrine cells or their precursors, and can occur in most organs. There are currently no QPIs available for NETs and their heterogeneity makes QPI development difficult. CommNETs is a collaboration between NET clinicians, researchers and advocates in Canada, Australia and New Zealand. We created QPIs for NETs using a three-step consensus process. Read More |
December 11, 2019
 The CX5 trial A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer (SHAPE) has met its accrual goal and is now closed to further randomizations. Read More |
 The MEC4 (Alliance A091201) trial, a Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma has permanently closed. Read More |
 CCTG LY18, A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma, has been centrally activated. The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen. Read More |
 The CCTG Central Office will be closed on some dates during the holidays with partial staff coverage, there is also information on shipment of specimens for banking and kit supply and BARL holiday schedule. Web-based applications (i.e. MANGO, GCP) will still be available and regular business hours will resume on Thursday, January 2, 2020 at 8:30 am EST. Read More |